http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011060332-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e1dbd49e062bd39999dc27e542cb8d8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6f660e8806eddd0423e72fa5879add0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3f7c6d1a3e2523db5490a9a8e34b914a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-133 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-131 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C215-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-133 |
| filingDate | 2010-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2499ef098691299f9e6597128ab7d484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc1fca5f5f1abcc8d560a4f099e2883e |
| publicationDate | 2011-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2011060332-A3 |
| titleOfInvention | Compositions and methods for treating hyperproliferative disorders |
| abstract | A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-increasing retinoid such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) at least one (and in certain embodiments at least two) compounds selected from the groups consisting of (i) a non-18 carbon chain length L-threo-sphinganine(s) or pharmaceuticeutically acceptable salt thereof, (ii) glucosylceramide or glucosyl(dihydro)ceramide synthesis inhibitor(s), and (iii) sphingomyelin or dihydrosphingomyelin synthase inhibitor(s). Preferred L-threo-sphinganines are of carbon chain length 17 carbons, 19 carbons and 20 carbons. A preferred glucosylceramide or glucosyl(dihydro)ceramide synthesis inhibitor is D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred sphingomyelin or dihydrosphingomyelin synthesis inhibitor is D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred hyperproliferative disorder is brain cancers. |
| priorityDate | 2009-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.